InvestorsHub Logo
Followers 5
Posts 514
Boards Moderated 0
Alias Born 06/08/2009

Re: stocksrising post# 334

Thursday, 01/04/2024 8:58:23 AM

Thursday, January 04, 2024 8:58:23 AM

Post# of 384
Ask, and you shall receive! Lol

Item 7.01
Regulation FD Disclosure.
bluebird bio, Inc. (the "Company") has signed a second outcomes-based agreement for LYFGENIA, bringing the cumulative total of covered lives for LYFGENIA to approximately 200 million, less than one month since FDA approval of LYFGENIA on December 8, 2023 for sickle cell disease in patients 12 and older with a history of vaso-occlusive events. Additional updates on the commercial launch of LYFGENIA will be presented at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News